| Biomarker ID | 108 |
| PMID | 16395409 |
| Year | 2006 |
| Biomarker | FPA |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated (0.58 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Normal vs Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Training set consisted of 32 patients with an average Gleason score of 7.7 and average age of 66 and 33 controls. Validated on 41 independent serum samples with patients having advance prostate cancer. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.000108 |
| Method Used | MALDI-TOF MS |
| Clinical | No |
| Remarks | 100% accuracy achieved on selected features (n=651,68,26) on validation set |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |